This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Lung Cancer - Surgery

June 28, 2015
Retrospective cross-sectional cohort study using 5 years of Medicare benficiary data to determine whether post discharge mortality varies by time-to-readmission. Two of the three operations analyzed were lung resection (n=101,092) and coronary artery bypass grafting (CABG) (n=484,260).
June 25, 2015
This study evaluated outcomes in patients undergoing resection for lung cancer who were found at surgery to have pleural carcinomatosis.  2.9% of registry patients were identified, of whom 49% had a macroscopic complete resection.  5-year survival in those without other metastatic disease was 29%.  5-year survival in those undergoing macroscopic comp
June 14, 2015
Trials evaluating the use of surgery in stage IIIB NSCLC are lacking. This study goes some way to address that and demonstrates that surgery as part of multi-modality therapy may result in a survival benefit.
June 12, 2015
This meta-analysis of published studies evaluated outcomes of multimodality therapy including resection for superior sulcus NSCLC invading the spine.  134 articles were evaluated, which included 135 patients.  63% had induction therapy, and all underwent en bloc resection.  52% had adjuvant therapy.  Survival at 3,5, and 10 years was 57%, 42%, and 27
May 22, 2015
In this retrospective review of 336 patients treated surgically for early stage NSCLC, the prognostic value of PET SUV was evaluated.  Risks of recurrence and death increased steadily as SUV increased. 
April 2, 2015
The authors retrospectively reviewed their institutional database to assess outcomes for VATS lobectomy vs SBRT for stage I NSCLC, comparing propensity score-matched groups (41 pairs).  Survival, cancer-specific survival, local recurrence, and distant recurrence were significantly better in the surgical group. 
February 21, 2015
Indications for postoperative radiation therapy (PORT) for resected lung cancer are unclear.  This study evaluated outcomes from the National Cancer Data Base 2004-2006, including 2115 patients resected with pathologic N2 NSCLC, of whom  918 (43%) received PORT.  PORT was associated with better median survival (42 vs 38 mos, p=0.048) and was associat
February 16, 2015
This trial randomized 61 pts to a program of endurance and strength training or no training beginning 5-7 weeks after lung resection for cancer and lasting 20 weeks.  Compared to controls, treatment group patients demonstrated significant improvements in peak O2 uptake, DLCO, leg and arm strength, muscle mass, and QOL.
February 3, 2015
This consensus statement from the European Neuroendocrine Society is based on extensive bibliographic searches and systematic review.  Surgery is the mainstay of therapy for most tumors, and includes resection of metastases when this can be accomplished in a curative manner.  Somatostatin analogues are considered first line therapy for unresectable c
February 2, 2015
The authors queried the National Cancer Data Base to assess outcomes of patients with R1 resection margins related to the presence and type of postoperative adjuvant therapy.  3.1% of over 54,000 resections had R1 margins, which negatively affected long-term survival.  Combined chemotherapy and radiation therapy improved outcomes; administration of c